HomeCompareEUZOF vs JNJ

EUZOF vs JNJ: Dividend Comparison 2026

EUZOF yields 6.91% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EUZOF wins by $1.3K in total portfolio value
10 years
EUZOF
EUZOF
● Live price
6.91%
Share price
$44.97
Annual div
$3.11
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$1,071.97
Full EUZOF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — EUZOF vs JNJ

📍 EUZOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEUZOFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EUZOF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EUZOF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EUZOF
Annual income on $10K today (after 15% tax)
$587.40/yr
After 10yr DRIP, annual income (after tax)
$911.17/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,074.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EUZOF + JNJ for your $10,000?

EUZOF: 50%JNJ: 50%
100% JNJ50/50100% EUZOF
Portfolio after 10yr
$30.9K
Annual income
$2,880.69/yr
Blended yield
9.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EUZOF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
0.4
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EUZOF buys
0
JNJ buys
0
No recent congressional trades found for EUZOF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEUZOFJNJ
Forward yield6.91%2.13%
Annual dividend / share$3.11$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$31.6K$30.3K
Annual income after 10y$1,071.97$4,689.40
Total dividends collected$8.9K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: EUZOF vs JNJ ($10,000, DRIP)

YearEUZOF PortfolioEUZOF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,391$691.06$10,592$272.30+$799.00EUZOF
2$12,924$735.69$11,289$357.73+$1.6KEUZOF
3$14,609$780.10$12,123$472.89+$2.5KEUZOF
4$16,456$824.10$13,141$629.86+$3.3KEUZOF
5$18,475$867.55$14,408$846.81+$4.1KEUZOF
6$20,679$910.29$16,021$1,151.60+$4.7KEUZOF
7$23,078$952.21$18,122$1,588.22+$5.0KEUZOF
8$25,687$993.19$20,930$2,228.20+$4.8KEUZOF
9$28,518$1,033.14$24,792$3,191.91+$3.7KEUZOF
10$31,586$1,071.97$30,274$4,689.40+$1.3KEUZOF

EUZOF vs JNJ: Complete Analysis 2026

EUZOFStock

Eurazeo SE is a private equity and venture capital firm specializing in growth capital, acquisitions, leveraged buyouts, and buyins of a private company, and investments in mid-market and listed public companies. . The company invest in equity in the small-mid and Mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, SMEs, high growth companies, and real estate management and investment activities. It does not have any restrictions regarding the sectors in which it invests but prefers to invest in smart cities, services, leisure and mobility, real estate, fintech, investment activities, distribution, industry, luxury, consumer goods, business services, consumer and retail brands, and health sectors. The firm seeks to invest in consumer brands with a focus on beauty, personal care, household care, juvenile products, apparel, wellness, accessories, home, jewelry, leisure, health, fitness, beverage, and food companies based in United States and Europe. It typically invests in companies with a differentiated concept and global growth potential. The firm identifies companies upstream, carefully selecting them primarily from sectors driven by digital transformation and focusing on changes in lifestyle and consumption (mobility, online buying, collaboration models, etc.). The firm invests in large properties in need of restructuring; residential, commercial, and office development projects; and companies with real estate assets in Western Europe. It primarily invests in United States, France, Italy, North America and other European countries. The firm typically invests between $10 million and €800 million ($892.55 million) in companies with enterprise values of more than €150/200 million ($163.74 million/$218.30 million) and €5000 million ($7108.9 million). It limits each investment to less than 10 percent to 15 percent of its net asset value. The firm can also invest where its equity or quasi-equity stake is between €175 million ($195.25 million) and €800 million ($892.55 million). The firm prefers to make investments with transactions above $100 million as co-investments. It prefers to acquire majority stakes in its portfolio companies along with minority stakes. The firm may invest in public companies either taking the public company to private, and then doing a leveraged buyout or in the form of private investment in public equity (PIPE). The firm invests for a period of five to seven years. It exits its investment by sale to a manufacturer, sale to a financial investor, or through an IPO. Eurazeo SE was founded in 1969 and is based in Paris, France with additional offices in North America, Asia, Europe and South America.

Full EUZOF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this EUZOF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EUZOF vs SCHDEUZOF vs JEPIEUZOF vs OEUZOF vs KOEUZOF vs MAINEUZOF vs ABBVEUZOF vs MRKEUZOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.